Systemic delivery of an oncolytic adenovirus expressing soluble transforming growth factor-β receptor ii-fc fusion protein can inhibit breast cancer bone metastasis in a mouse model

Human Gene Therapy

Volumn 21, Issue 11, 2010, Pages 1623-1629

  Hu, Zebin ^a   Zhang, Zhenwei ^a   Guise, Theresa ^b,c   Seth, Prem ^a  

^a EVANSTON HOSPITAL   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

^c INDIANA UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM; HYBRID PROTEIN; LUCIFERASE; ONCOLYTIC ADENOVIRUS; PHOSPHATE BUFFERED SALINE; SOLUBLE TRANSFORMING GROWTH FACTOR BETA RECEPTOR II FC FUSION PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE METASTASIS; BONE RADIOGRAPHY; BONE TISSUE; BREAST CANCER; CALCIUM BLOOD LEVEL; CANCER CELL; CANCER MODEL; CONTROLLED STUDY; DRUG EFFECT; FEMALE; HEART LEFT VENTRICLE; HUMAN; HUMAN CELL; METASTASIS INHIBITION; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; NORMAL VALUE; OSTEOLYSIS; TREATMENT OUTCOME; TUMOR VOLUME; VIRUS EXPRESSION; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; BONE NEOPLASMS; BREAST NEOPLASMS; CELL LINE, TUMOR; DISEASE MODELS, ANIMAL; FEMALE; GENE THERAPY; HUMANS; IMMUNOGLOBULIN FC FRAGMENTS; MICE; MICE, NUDE; ONCOGENE PROTEINS, FUSION; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PROTEIN-SERINE-THREONINE KINASES; RECEPTORS, TRANSFORMING GROWTH FACTOR BETA; VIRUS REPLICATION;

ADENOVIRIDAE; MUS; MUS MUSCULUS;

EID: 78649365226     PISSN: 10430342     EISSN: None     Source Type: Journal    
DOI: 10.1089/hum.2010.018     Document Type: Article

References (24)

1. Akhtari, M., Mansuri, J., Newman, K.A., Guise, T.M., and Seth, P. (2008). Biology of breast cancer bone metastasis. Cancer Biol. Ther. 7, 3-9.
2. American Cancer Society,(2010). Cancer Facts & Figures., Available at, http://www.cancer.org/docroot/STT/stt-0.asp (accessed August 2010).
3. Crompton, A.M., and Kirn, D.H. (2007). From ONYX-015 to armed vaccinia viruses: The education and evolution of onco-lytic virus development. Curr. Cancer Drug Targets 7, 133-139.
4. Howe, J.A., Demers, G.W., Johnson, D.E., Neugebauer, S.E., Perry, S.T., Vaillancourt, M.T., and Faha, B. (2000). Evaluation of E1-mutant adenoviruses as conditionally replicating agents for cancer therapy. Mol. Ther. 2, 485-495.
5. Hu, Z., Robbins, J.S., Pister, A., Zafar, M.B., Zhang, Z.W., Gupta, J., Lee, K.J., Neuman, K., Yun, C.O., Guise, T., and Seth, P. (2010). A modified hTERT promoter-directed oncolytic ade-novirus replication with concurrent inhibition of TGFb signaling for breast cancer therapy. Cancer Gene Ther. 17, 235-243.
6. Iyer, I., Wang, Z.-G., Akhtari, M., Zhao, W., and Seth, P. (2005). Targeting TGF b signaling for cancer therapy. Cancer Biol. Ther. 4, e33-e38.
7. Kang, Y., He, W., Tulley, S., Gupta, G.P., Serganova, I., Chen, C.R., Manova-Todorova, K., Blasberg, R., Gerald, W.L., and Massague, J. (2005). Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc. Natl. Acad. Sci. U.S.A. 102, 13909-13914.
8. Katayose, D., Gudas, J., Nguyen, H., Srivastava, S., Cowan, K.H., and Seth, P. (1995). Cytotoxic effects of adenovirus-mediated wild-type p53 protein expression in normal and tumor mammary epithelial cells. Clin. Cancer Res. 1, 889-897.
9. Kingsley, L.A., Fournier, P.G., Chirgwin, J.M., and Guise, T.A. (2007). Molecular biology of bone metastasis. Mol. Cancer Ther. 6, 2609-2617.
10. Korpal, M., Yan, J., Lu, X., Xu, S., Lerit, D.A., and Kang, Y. (2009). Imaging transforming growth factor-b signaling dynamics and therapeutic response in breast cancer bone metastasis. Nat. Med. 15, 960-966.
11. Lacroix, M., Toillon, R.A., and Leclercq, G. (2006). p53 and breast cancer, an update. Endocr. Relat. Cancer 13, 293-325.
12. McCormick, F. (2005). Future prospects for oncolytic therapy. Oncogene 24, 7817-7819.
13. Padua, D., and Massague, J. (2009). Roles of TGFb in metastasis. Cell Res. 19, 89-102.
14. Serganova, I., Moroz, E., Vider, J., Gogiberidze, G., Moroz, M., Pillarsetty, N., Doubrovin, M., Minn, A., Thaler, H.T., Mas-sague, J., Gelovani, J., and Blasberg, R. (2009). Multimodality imaging of TGFb signaling in breast cancer metastases. FASEB J. 23, 2662-2672.
15. Seth, P., ed. (1999). Adenoviruses: Basic Biology to Gene Therapy. (R.G. Landes, Austin, TX). pp 1-314.
16. Seth, P., Brinkmann, U., Schwartz, G.N., Katayose, D., Gress, R., Pastan, I., and Cowan, K. (1996). Adenovirus-mediated gene transfer to human breast tumor cells: An approach for cancer gene therapy and bone marrow purging. Cancer Res. 56, 1346-1351.
17. Seth, P., Wang, Z.G., Pister, A., Zafar, M.B., Kim, S., Guise, T., and Wakefield, L. (2006). Development of oncolytic adenovi-rus armed with a fusion of soluble transforming growth fac-tor-b receptor II and human immunoglobulin Fc for breast cancer therapy. Hum. Gene Ther. 17, 1152-1160.
18. Shipitsin, M., Campbell, L.L., Argani, P., Weremowicz, S., Bloushtain-Qimron, N., Yao, J., Nikolskaya, T., Serebryiskaya, T., Beroukhim, R., Hu, M., Halushka, M.K., Sukumar, S., Parker, L.M., Anderson, K.S., Harris, L.N., Garber, J.E., Richardson, A.L., Schnitt, S.J., Nikolsky, Y., Gelman, R.S., and Polyak, K. (2007). Molecular definition of breast tumor heterogeneity. Cancer Cell 11, 259-273.
19. Steeg, P.S. (2006). Tumor metastasis: Mechanistic insights and clinical challenges. Nat. Med. 12, 895-904.
20. Waddington, S.N., McVey, J.H., Bhella, D., Parker, A.L., Barker, K., Atoda, H., Pink, R., Buckley, S.M., Greig, J.A., Denby, L., Custers, J., Morita, T., Francischetti, I.M., Monteiro, R.Q., Barouch, D.H., Van Rooijen, N., Napoli, C., Havenga, M.J., Nicklin, S.A., and Baker, A.H. (2008). Adenovirus serotype 5 hexon mediates liver gene transfer. Cell 132, 397-409.
21. Wang, Z.G., Zhao, W., Ramachandra, M., and Seth, P. (2006). An oncolytic adenovirus expressing soluble transforming growth factor-b type II receptor for targeting breast cancer: In vitro evaluation. Mol. Cancer Ther. 5, 367-373.
22. Yang, Y.A., Dukhanina, O., Tang, B., Mamura, M., Letterio, J.J., Macgregor, J., Patel, S.C., Khozin, S., Liu, Z.Y., Green, J., An-ver, M.R., Merlino, G., and Wakefield, L.M. (2002). Lifetime exposure to a soluble TGF-b antagonist protects mice against metastasis without adverse side effects. J. Clin. Invest. 109, 1607-1615.
23. Yin, J.J., Selander, K., Chirgwin, J.M., Dallas, M., Grubbs, B.G., Wieser, R., Massague, J., Mundy, G.R., and Guise, T.A. (1999). TGF-b signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J. Clin. Invest. 103, 197-206.
24. Yin, J.J., Mohammad, K.S., Kakonen, S.M., Harris, S., Wu-Wong, J.R., Wessale, J.L., Padley, R.J., Garrett, I.R., Chirgwin, J.M., and Guise, T.A. (2003). A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc. Natl. Acad. Sci. U.S.A. 100, 10954-10959.